Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19

被引：0
|
作者：
Jianhua Liu
Dongsheng Tu
Janet Dancey
Leonard Reyno
Kathleen I. Pritchard
Joseph Pater
Lesley K Seymour
机构：
[1] Cancer Research Institute,National Cancer Institute of Canada Clinical Trials Group
[2] Queens University,undefined
来源：
Breast Cancer Research and Treatment | 2006年 / 100卷
关键词：
Quality of life; Analyses; Statistical methods; DPPE; Breast cancer; Tesmilifene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：263 / 271
页数：8
相关论文
共 50 条
  • [1] Quality of life analyses in a clinical trial of DPPE (tesmilifene) plus doxorubicin versus doxorubicin in patients with advanced or metastatic breast cancer: NCICCTG trial MA.19
    Liu, Jianhua
    Tu, Dongsheng
    Dancey, Janet
    Reyno, Leonard
    Pritchard, Kathleen I.
    Pater, Joseph
    Seymour, Lesley K.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 263 - 271
  • [2] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study
    Philippe A. Cassier
    Sylvie Chabaud
    Véronique Trillet-Lenoir
    Pierre-Yves Peaud
    Jean-Dominique Tigaud
    Hervé Cure
    Hubert Orfeuvre
    Bruno Salles
    Claude Martin
    Jean-Philippe Jacquin
    Cecile Agostini
    Jean-Paul Guastalla
    David Pérol
    Thomas Bachelot
    Breast Cancer Research and Treatment, 2008, 109 : 343 - 350
  • [3] A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer:: results of the ERASME 3 study
    Cassier, Philippe A.
    Chabaud, Sylvie
    Trillet-Lenoir, Veronique
    Peaud, Pierre-Yves
    Tigaud, Jean-Dominique
    Cure, Herve
    Orfeuvre, Hubert
    Salles, Bruno
    Martin, Claude
    Jacquin, Jean-Philippe
    Agostini, Cecile
    Guastalla, Jean-Paul
    Perol, David
    Bachelot, Thomas
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (02) : 343 - 350
  • [4] A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer
    Chow, Louis Wing-Cheong
    Yip, Adrian Yun-San
    Lang, Brian Hung-Hin
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (02): : 133 - 138
  • [5] Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3
    Vickers, M. M.
    Lee, C.
    Tu, D.
    Wheatley-Price, P.
    Parulekar, W.
    Brundage, M. D.
    Moore, M. J.
    Au, H.
    O'Callaghan, C. J.
    Jonker, D. J.
    Ringash, J.
    Goldstein, D.
    PANCREATOLOGY, 2016, 16 (06) : 1106 - 1112
  • [6] Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial
    Van Tine, Brian A.
    Krarup-Hansen, Anders
    Hess, Lisa M.
    Abdul Razak, Albiruni R.
    Soldatenkova, Victoria
    Wright, Jennifer
    Park, Se Hoon
    RARE TUMORS, 2022, 14
  • [7] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)
    A Bensalem
    K Bouzid
    Breast Cancer Research, 7
  • [8] A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer MBC
    Bensalem, A
    Bouzid, K
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 1) : S21 - S21
  • [9] The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
    Al-Batran, S. -E.
    Bischoff, J.
    von Minckwitz, G.
    Atmaca, A.
    Kleeberg, U.
    Meuthen, I.
    Morack, G.
    Lerbs, W.
    Hecker, D.
    Sehouli, J.
    Knuth, A.
    Jager, E.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1615 - 1620
  • [10] The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
    S-E Al-Batran
    J Bischoff
    G von Minckwitz
    A Atmaca
    U Kleeberg
    I Meuthen
    G Morack
    W Lerbs
    D Hecker
    J Sehouli
    A Knuth
    E Jager
    British Journal of Cancer, 2006, 94 : 1615 - 1620
12345